Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

BACKGROUND The ability to control human immunodeficiency virus (HIV) replication in vivo in the absence of antiretroviral therapy (ART) is a measure of the efficiency of antiviral immunity. In a study of patients with chronic, ART-suppressed HIV infection, AIDS Clinical Trials Group 5068 investigated the effects of immunization with an exogenous HIV vaccine and pulse exposure to the subject's unique viral epitopes, by means of structured treatment interruptions (STIs), on the dynamics of viral rebound during a subsequent analytical treatment interruption (ATI). METHODS Ninety-seven subjects receiving stable ART with an HIV-1 RNA load <50 copies/mL and CD4(+) T lymphocyte count >400 cells/mm(3) were randomized to undergo continued ART, STIs, ALVAC-HIV vCP1452 immunization, or STIs and ALVAC-HIV vCP1452 immunization. RESULTS Subjects in the 2 STI arms had a significantly longer median doubling time in the period of the initial rise of viral load, a significantly lower median peak viral load, a significantly lower median end-of-ATI viral load set point, and a greater proportion of subjects with an end-of-ATI viral load set point <1,000 copies/mL, compared with the subjects in the 2 arms without STIs. With an immunization schedule of 3 sets of 3 weekly injections, ALVAC-HIV vCP1452 did not affect viral load measures. CONCLUSIONS In this randomized, controlled study of intermittent STI as a therapeutic autoimmunization strategy, evidence of enhanced immunologic control of HIV replication was demonstrated.

[1]  C. Rouzioux,et al.  Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals , 2006, AIDS.

[2]  W. Blattner,et al.  High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. , 2005, The Journal of infectious diseases.

[3]  B. Autran,et al.  Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. , 2005, The Journal of infectious diseases.

[4]  V. Calvez,et al.  Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). , 2005, Vaccine.

[5]  C. Rouzioux,et al.  Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients , 2005, AIDS.

[6]  L. Montaner,et al.  Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection , 2004, PLoS medicine.

[7]  E. Rosenberg,et al.  Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.

[8]  G. M. Ortiz,et al.  Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3 , 2004, Journal of acquired immune deficiency syndromes.

[9]  K. Metzner,et al.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.

[10]  K. Hertogs,et al.  Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. , 2003, The Journal of infectious diseases.

[11]  A. Telenti,et al.  A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. , 2003, Archives of internal medicine.

[12]  V. Johnson,et al.  Accuracy of the TRUGENE HIV-1 Genotyping Kit , 2003, Journal of Clinical Microbiology.

[13]  D. Kuritzkes,et al.  Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System , 2003, Journal of Clinical Microbiology.

[14]  H. Günthard,et al.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Perelson,et al.  Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. , 2002, The Journal of infectious diseases.

[16]  H. Günthard,et al.  Drug Resistance Mutations during Structured Treatment Interruptions , 2002, Antiviral therapy.

[17]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[18]  M. Hudgens,et al.  Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A , 2002, Journal of acquired immune deficiency syndromes.

[19]  D. Ho,et al.  Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy , 2002, Journal of Virology.

[20]  M. L. Clements-Mann,et al.  Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. , 2001, The Journal of infectious diseases.

[21]  C. Yoder,et al.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression , 2000, AIDS.

[22]  D. Montefiori,et al.  Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.

[23]  M. Lederman,et al.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. , 1998, The Journal of infectious diseases.

[24]  J. Yewdell,et al.  The Human Immunodeficiency Virus Type 1 (HIV-1) Vpu Protein Interferes with an Early Step in the Biosynthesis of Major Histocompatibility Complex (MHC) Class I Molecules , 1997, The Journal of experimental medicine.

[25]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[26]  F. Lemonnier,et al.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein , 1996, Nature Medicine.

[27]  D. Singer,et al.  Repression of MHC class I gene promoter activity by two-exon Tat of HIV. , 1993, Science.

[28]  H. Lyerly,et al.  HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. , 1989, Journal of immunology.

[29]  G. Shaw,et al.  Extensive variation of human immunodeficiency virus type-1 in vivo , 1988, Nature.

[30]  R. Desrosiers,et al.  Viral persistence: HIV's strategies of immune system evasion. , 2002, Annual review of medicine.

[31]  J. Peacock,et al.  StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial , 2016, Trials.